Home | Structured Search | Drug Resource
Find: within
Gout > Patient Education Author: Grace P. Teal, MD; Howard A. Fuchs, MD
Module updated - 2009-11-23
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Rationale:

  • All medications used to treat gout could have substantial side effects that necessitate ongoing monitoring. Blood counts and renal function may decrease at any time during therapy and need regular monitoring.

Evidence:

  • Consensus.

Comments:

  • Patients with renal insufficiency are at much higher risk for hypersensitivity reactions (allopurinol), further decline in renal function (NSAIDs), marrow injury (allopurinol and colchicine), and neurologic effects (colchicine).

FAQs
Grace P. Teal, MD (deceased) has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Howard A. Fuchs, MD, is a consultant for TAP Pharmaceuticals.
Darren B. Taichman, MD, PhD, Editor, PIER, has received grant support from Actelion Pharmaceuticals Ltd , and honoraria for continuing medical education grand rounds and lectures given.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2010 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.